NY-EMPIRE-STATE-REALTY
16.6.2024 20:42:34 CEST | Business Wire | Press release
A 270-foot-long dragon has landed in the center of New York City – atop the iconic Empire State Building (ESB). In partnership with Max, ESB has acknowledged that Vhagar the Dragon has coiled herself around its mast just as ESB and Max cap off their weeklong “House of the Dragon” takeover.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240616631517/en/
Empire State Building Debuts 270-Foot Vhagar the Dragon Coiled Around the Building’s Mast, in Partnership with Max (Photo: Business Wire)
The best views of Vhagar are in Manhattan from the south of ESB, and unique selfie moments are available from ESB itself where she scans for prey with her huge head extended over the southern deck of ESB’s 86th Floor Observatory. ESB’s lights have been set so fans can witness a series of dynamic light shows which feature the dragon against schemes of gold, green, and red.
“Just after the Empire State Building pledged its allegiance to the King, Vhagar descended upon the heart of New York City and has claimed the mast of the ‘World’s Most Famous Building’ as her perch,” said ESRT Chairman and CEO Tony Malkin. “Citizens of Westeros can now sit in the Iron Throne at the Observatory’s grand staircase and then rise to the 86th Floor to face the colossal beast up close as they take in the unmatched, 360-degree views from our world-famous Observatory – Tripadvisor’s #1 attraction in the United States.”
Affixed by more than 153 rigging points, Vhagar is made up of 1,700 total patterns and 600,000 inches of sewn seams. The giant dragon was created in partnership with creative agency Giant Spoon and fabricated by Bigger Than Life Advertising Inc. The company’s President Mark Bachman was a manager on the Empire State Building’s King Kong installation in 1983.
The “House of the Dragon” takeover included a photo opportunity with the iconic Iron Throne, a visit from the “House of the Dragon” cast, and an interactive photo booth on the 80th Floor. This partnership with Max is just one of several recent events at the Empire State Building which have garnered global attention, which include partnerships with Mercedes-AMG Petronas F1 x WhatsApp, Outward Bound, and “Star Wars.”
The Empire State Building Observatory recently underwent a $165 million reimagination that included the addition of a dedicated visitor entrance, an immersive museum with nine galleries, brand-new, bespoke Observatory Host uniforms, and a new 102nd Floor Observatory with unmatched views. The reimagined Observatory Experience has been voted the #1 attraction in the U.S. in Tripadvisor’s Travelers’ Choice Awards: Best of the Best for two consecutive years.
Tickets to see the dragon at the Empire State Building Observatory can be purchased here. Text CONNECT to 274-16 to receive real-time information about the Empire State Building’s tower lights.
Hi-res imagery and video of all elements of the House of the Dragon takeover can be found here.
About the Empire State Building
The Empire State Building, the “World's Most Famous Building," owned by Empire State Realty Trust, Inc. (ESRT: NYSE), soars 1,454 feet above Midtown Manhattan from base to antenna. The $165 million reimagination of the Empire State Building Observatory Experience creates an all-new experience with a dedicated guest entrance, an interactive museum with nine galleries, and a redesigned 102nd Floor Observatory with floor-to-ceiling windows. The journey to the world-famous 86th Floor Observatory, the only 360-degree, open-air observatory with views of New York and beyond, orients visitors for their entire New York City experience and covers everything from the building's iconic history to its current place in pop culture. The Empire State Building Observatory Experience welcomes millions of visitors each year and was declared "America's Favorite Building" by the American Institute of Architects, the world's most popular travel destination by Uber, the #1 attraction in the U.S. in Tripadvisor’s Travelers’ Choice Awards: Best of the Best for two consecutive years, and the #1 New York City attraction in Lonely Planet’s Ultimate Travel List.
Since 2011, the building has been fully powered by renewable wind electricity, and its many floors house a diverse array of office tenants such as LinkedIn and Shutterstock, as well as retail options like STATE Grill and Bar, Tacombi, and Starbucks. For more information and Observatory Experience tickets visit esbnyc.com or follow the building's Facebook, X (formerly Twitter), Instagram, Weibo, YouTube, or TikTok.
About House of the Dragon
Based on George R.R. Martin’s “Fire & Blood,” the series, set 200 years before the events of “Game of Thrones,” tells the story of House Targaryen. Co-Creator/Executive Producer George R.R. Martin; Co-Creator/Showrunner/Executive Producer, Ryan Condal; Executive Producers Sara Hess, Alan Taylor, Melissa Bernstein, Kevin de la Noy, Loni Peristere, Vince Gerardis. Season two returning cast includes Matt Smith, Olivia Cooke, Emma D’Arcy, Eve Best, Steve Toussaint, Fabien Frankel, Ewan Mitchell, Tom Glynn-Carney, Sonoya Mizuno, and Rhys Ifans. Additional returning cast includes Harry Collett, Bethany Antonia, Phoebe Campbell, Phia Saban, Jefferson Hall, and Matthew Needham. New season two cast are Abubakar Salim as Alyn of Hull, Gayle Rankin as Alys Rivers, Freddie Fox as Ser Gwayne Hightower, Simon Russell Beale as Ser Simon Strong, Clinton Liberty as Addam of Hull, Jamie Kenna as Ser Alfred Broome, Kieran Bew as Hugh, Tom Bennett as Ulf, Tom Taylor as Lord Cregan Stark, and Vincent Regan as Ser Rickard Thorne.
Source: Empire State Realty Trust
Category: Observatory
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240616631517/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
